Saturday, 22 August 2026 SourcesAbout🌓
🇮🇳 IN ▾
BREAKING
NGT issues notice to Centre against amendment on Ganga floodplains Risks weakening worker safeguards: Cong on SC's industry definition ruling Forde five-for and Kamil Pooran 81* keep Kings' rise going Interpol Red Corner Notice issued against 2024 Sambhal violence ‘mastermind’ Shariq Sata Brazil Football Body Responds To 'Boycott' Calls In India, Clears Stance On Friendly Match U.S. is set to impose 50% tariffs on $20 billion worth of Canadian products Ripples of JU clash reaches Presidency University and Midnapore College West Asia LIVE: Trump says Iran not ready to make the 'right deal' Gold Rate Today, August 22: Check 18, 22 and 24 carat gold prices in Chennai, Mumbai, Delhi, Kolkata and other cities What’s going on in Chennai for Madras Day NGT issues notice to Centre against amendment on Ganga floodplains Risks weakening worker safeguards: Cong on SC's industry definition ruling Forde five-for and Kamil Pooran 81* keep Kings' rise going Interpol Red Corner Notice issued against 2024 Sambhal violence ‘mastermind’ Shariq Sata Brazil Football Body Responds To 'Boycott' Calls In India, Clears Stance On Friendly Match U.S. is set to impose 50% tariffs on $20 billion worth of Canadian products Ripples of JU clash reaches Presidency University and Midnapore College West Asia LIVE: Trump says Iran not ready to make the 'right deal' Gold Rate Today, August 22: Check 18, 22 and 24 carat gold prices in Chennai, Mumbai, Delhi, Kolkata and other cities What’s going on in Chennai for Madras Day
World

More than 16,000 doses of Ervebo vaccine arrive in Ebola-hit DRC

The Hindu - International ·
More than 16,000 doses of Ervebo vaccine arrive in Ebola-hit DRC

Account subscription benefits alongside Premium Stories, Editorials, Opinions and more. Unlock these with Subscription

A member of the M23 rebel group stands guard as Provincial authorities visit the Rodolphe Merieux Laboratory, National Biomedical Research Institute (INRB), where samples from suspected Ebola cases are tested, as part of the response to the epidemic in Goma, North Kivu Province of the Democratic Republic of Congo. File | Photo Credit: Reuters

More than 16,000 doses of the Ervebo vaccine arrived in the Democratic Republic of Congo (DRC) late Friday (August 21, 2026), an AFP journalist saw, as the country faces its deadliest Ebola outbreak in history.

The DRC's 17th Ebola outbreak, which has killed thousands of people, was declared on May 15 but is thought to have been spreading for several weeks prior.

It has hit regions in the north and east where the presence of the state is weak, health infrastructure is largely lacking and myriad armed groups have roamed for decades.

The World Health Organisation (WHO) announced on Thursday (August 20) that the DRC would receive 70,000 doses of the Ervebo vaccine, produced in Germany.

The vaccine, developed by the pharmaceutical company Merck, is approved against the Zaire strain of the virus, but not against the Bundibugyo strain currently circulating in the country.

WHO experts still do not know whether Ervebo protects humans against the Bundibugyo strain, but early data, notably from animal trials, suggest it could offer some protection.

The Ervebo vaccine "has already been used several times, and in particular on a very large scale during the 2018-2020 outbreak", Samuel Roger Kamba, the DRC's Minister of Health, told the press.

He was speaking on the tarmac of Kinshasa airport, where a batch of 16,250 doses was delivered by plane on Friday (August 21).

Of the 70,000 doses made available to the DRC, 20,000 are intended for a clinical trial, and 50,000 for "frontline and health workers" in the DRC, the WHO explained on Thursday (August 20).

The Ebola outbreak in the DRC has already caused 2,516 deaths among 5,290 confirmed cases, according to the latest data published by the Congolese authorities.

It "is growing exponentially", warned Julien Harneis, the UN's senior Ebola coordinator, on Friday (August 21).

This month, WHO vaccine experts recommended a full-scale human trial of Ervebo, the only existing approved Ebola vaccine, to see if it offered cross-protection against the Bundibugyo strain.

Read the full article on The Hindu - International ›

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.thehindu.com — the content belongs to The Hindu - International.

More from The Hindu - International

See all ›

More in World

See all ›